These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37184108)

  • 1. Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer.
    Liang X; Gao X; Wang F; Li S; Zhou Y; Guo P; Meng Y; Lu T
    Cancer Med; 2023 Jul; 12(13):14171-14182. PubMed ID: 37184108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of Efficacy and Prognosis Analysis of Stage III-IV SMARCA4-deficient 
Non-small Cell Lung Cancer Treated by PD-1 Immune Checkpoint Inhibitors plus 
Chemotherapy and Chemotherapy].
    Wang X; Tu M; Jia H; Liu H; Wang Y; Wang Y; Jiang N; Lu C; Zhang G
    Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):659-668. PubMed ID: 37985152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor.
    Zhou P; Fu Y; Tang Y; Jiang L; Wang W
    PeerJ; 2024; 12():e16923. PubMed ID: 38374950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of Clinicopathologic Features of 9 Cases of 
SMARCA4-deficient Non-small Cell Lung Cancer].
    Zhao R; Zou Y; Chen H; Chen Y; Liu Y; He M
    Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):575-582. PubMed ID: 36002194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular, clinicopathological characteristics and surgical results of resectable SMARCA4-deficient thoracic tumors.
    Luo J; Ding B; Campisi A; Chen T; Teng H; Ji C
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4455-4463. PubMed ID: 36121510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomorphologic and immunophenotypical analysis of SMARCA4 (BRG1)-deficient non-small cell lung carcinoma.
    Ogunbona OB; Lin X; Hornick JL; Lubin DJ; Wang Q; Reid MD; Schneider F; Li D; Shin DM; Shi Q
    J Am Soc Cytopathol; 2022; 11(4):183-193. PubMed ID: 35491322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.
    Shi M; Pang L; Zhou H; Mo S; Sheng J; Zhang Y; Liu J; Sun D; Gong L; Wang J; Zhuang W; Huang Y; Chen Z; Zhao Y; Li J; Huang Y; Yang Y; Fang W; Zhang L
    Lung Cancer; 2024 Jun; 192():107818. PubMed ID: 38763102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological characteristics and treatment outcomes of advanced SMARCA4-deficient thoracic tumors.
    Wang A; Jin Y; Cao Z; Lu L; Li Z
    Cancer Med; 2024 Jan; 13(1):e6809. PubMed ID: 38124509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas.
    Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D
    Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
    Bell EH; Chakraborty AR; Mo X; Liu Z; Shilo K; Kirste S; Stegmaier P; McNulty M; Karachaliou N; Rosell R; Bepler G; Carbone DP; Chakravarti A
    Clin Cancer Res; 2016 May; 22(10):2396-404. PubMed ID: 26671993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathological features and prognosis of SMARCA4-deficient non-small cell lung carcinoma: an analysis of 127 cases].
    Li SL; Wu CY; Zhang LP; Huang Y; Wu W; Zhang W; Hou LK
    Zhonghua Bing Li Xue Za Zhi; 2023 Jul; 52(7):665-670. PubMed ID: 37408395
    [No Abstract]   [Full Text] [Related]  

  • 12. Perspectives and Issues in the Assessment of
    Armon S; Hofman P; Ilié M
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding the Immunophenotype Spectrum of SMARCA4-Deficient Non-Small Cell Lung Carcinomas: A Case Series with Neuroendocrine Markers Expression.
    Mao R; Liu M; Shu X; Li W; Yan W; Li X
    Int J Surg Pathol; 2022 May; 30(3):251-259. PubMed ID: 34633874
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytomorphologic features of SMARCA4-deficient non-small cell lung carcinoma and correlation with immunohistochemical and molecular features.
    Sun T; Gilani SM; Podany P; Harigopal M; Zhong M; Wang H
    Cancer Cytopathol; 2022 Aug; 130(8):620-629. PubMed ID: 35468657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SMARCA4‑deficient non‑small cell lung cancer with an
    Sun L; Fu Q; Chen L; Di M; Cao J
    Oncol Lett; 2023 Dec; 26(6):513. PubMed ID: 37927421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer.
    Chen J; Zheng Q; Wang J; Zhang X; Lv Y
    Medicine (Baltimore); 2024 Feb; 103(8):e36959. PubMed ID: 38394494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
    Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
    J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.
    Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
    Zhou P; Fu Y; Tang Y; Jiang L; Wang W
    Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
    Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
    Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.